Today' s FDA pdufa announcement has nothing to do with the October 20 date for Xyosted, the company's most important product. It is an entirely different and far less significant product, which I'm sure is very important to the company, but not the reason that you are in the stock.
FDA announces acceptance of supplemental drug filing for makena SC . Why is AMAG tanking pre-market? Maybe its just a few shares!
Just normal profit taking after a big spike. If you sell now and epi gets approved today, it might cost you quite a bit more to get back in. Either that and you might time things perfectly and make a .10 swing trade assuming you're buying back in. It's too risky for me, at this point, to try and time the approvals or potential buyout rumor mill action.
Correlate T.A.M. to REV to SP...ATRS will upscale its TAM ( total available market for its for sale products) by 3 to 6X by Nov. 1-17. This is akin to say APPLE about to enter personal comunication products market with the first I-phone. YES, its that big of an event. However, being in a market almost guarantees a share of that market but SP correlation is based on market share% = rev/cost of achieving rev.
My take: if on Oct.19-17 the SP is $3.50 and the company is hinting at a dismal approach to entering the TESTOS. market, the share price can double if yearly REV's double---so the low side is $7-ish awaiting a signal on sales and profits on said sales.
So on Oct.21st, I believe the EV baseline is set to 900M$ ( $7X 150M shares- discount for uncertainty). I think most shareholders would clap and be very appreciative of that EV level.
But a big company looking at ATRS potential would NEVER-EVER be happy with that EV level. NEVER. And that idea should be the driver for APPLE to sell the company at a much higher EV than $900M by Nov.30-17.
Does any shareholder really think that ATRS can negotiate all the turbulence of a huge market opportunity better than say a TEVA?
Why should shareholders have to assume the risk of ATRS trying to gain a respectable share in ANY of the markets it products play in?
Why should anybody, including insiders, squander a truly GOLDEN moment, when the future opportunity shines like a sweet juicy PLUM about to be eaten...but then find out the other side of the PLUM has already been eaten and our side of the PLUM might have some rot or pestilence?
OCT.21-17 CAN TRUELY BE A ONCE IN A LIFETIME OF OWNING STOCKS TYPE MOMENT---WHEN ALL THE REWARD IS JACKED TO ITS HIGHEST AND ALL THE RISK HAS DISAPPEARED AND THE PLUM--ALL OF IT---IS PLUMP JUICY RIPE SWEET AND ALL OURS TO ENJOY.
Don't BLOW IT APPLE. DON'T!!!!!!!!!!
Gee, Dennis,maybe I have a little bit of a clue as to how things can pan out . Blind hope doesn't always workout. Not my first trip through the woodshed.
I have a fair amount of shares & would have made a handsome profit selling if not all my shares a portion of,But,I have held AIS/ATRS so long it become's like an old pair of shoes that fits perfectly....So,me thinks I will continue to sit and ponder.By the way this is the 'workings of an idle mind.
Last year we were sweating delisting and today we are getting added to Russell 3000 and getting buy recomendations. What do you think will be happening by this time next year?
52 week high is coming today !
I am back and I could not be happier with the direction the company is headed. I predict that by the end of the year we will be very well north of $10.
Nice timing. Chardan Capital Initiates coverage with a buy, price target $5, on the R2K date. ATRS was already going to see a very interesting, very high volume day, this makes it even more interesting.
Antares Pharma, Inc. (NASDAQ:ATRS) - Chardan Capital Initiates Coverage On Antares Pharma with Buy Rating, Announces $5.00 Price Target
Get News First. Profit Faster With Benzinga Professional get unlimited access to ALL...
Another delay, surprise, surprise.
27,380,434 From NASDAQ LOOK AT THE VOLUME REPORTED ATRS's NASDAQ Last Sale (NLS)_____NLS Volume___Previous Close____Today's High / Low _________________________________27,380,434______$3.01____________ 3.24 / 3.07
Donkey and Will goes onto the Mute board for spamming the board. Two "investors " that probably bought in at 5.40 way back when and never got over its. No need to reply boys I wont be able to see your posts.
Looking for Growth? Try the Companies Being Added to the Russell 3000
“It is the best of times. It is the worst of times.” With the equities markets acting crazily every day, an investor has a hard time picking winners
There are five products in the pipeline that are awaiting approval. I hope that ATRS is looking to add more products to the preclinical side soon. Keep that pipeling full.
The trees are shaking and fewer and fewer leaves are falling. The price should move up.
Friday = Russell Day 😎😎
Antares Pharma (NASDAQ:ATRS) initiated with Buy rating and $5 price target by H.C. Wainwright.
Sumatriptan's SURPRISE & MORE SURPRISES, Stockvadar-rallies
Now that Wyeth has backed off the sumatriptan market, all indicators are screaming that Antares' injector to Teva is stealing enormous market share MUCH HIGHER THAN EXPECTATIONS, so expect good revenue here. Also, just a brief tip - Oxtrexup is doing well, actually very well.
Now rumors are flying around AMAG today and no wonder. Makena sales are off to the races and once loaded into the Antares injector, this is going to be a whopper revenue winner, possibly even exceeding other projects.
People say, 'Well all this in Q4.' BIG MISTAKE! Antares is about to pop much higher as we believe in the next two weeks there will be a major news release. The pop is going to be sudden, swift, and way upward.
Keep your eyes pinned on the FDA!
-sv (STRONG BUY/HOLD)
I think Will was Whogo or maybe Ryman :o) He deleted his posts when asked what brought the new ID to our board today ........